Choliatron

Selected form

Trepibutone

Method of action: Bile And Liver Therapy

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Choliatron

What is Choliatron? Defining the Entity and Mechanism

Property	Description
Active ingredient	Trepibutone
Form	Tablets or Capsules (Oral)
Pharmacological class	Synthetic Choleretic and Spasmolytic Agent
General purpose	Alleviating functional gastrointestinal discomfort
Origin	Synthetic Compound (Butyrophenones)

Choliatron is a distinct pharmaceutical agent defined by its active ingredient, Trepibutone (INN), which is classified as a synthetic compound within the butyrophenone chemical class. This medicine is specifically intended for managing functional disorders related to the digestive system, a utility that is widely recognized for its pharmacological properties. Its official classification places it within the group of drugs intended for functional gastrointestinal disorders, holding the Anatomical Therapeutic Chemical (ATC) code A03AX09.

What is Choliatron Made of and How is it Taken?

The core of Choliatron is the single active substance, Trepibutone, which is formulated for oral delivery. As a single-ingredient, synthetic compound, Trepibutone is combined with standard solid pharmaceutical excipients necessary for its manufacture. The medicine is primarily presented in solid dosage forms, specifically tablets or capsules. This design ensures the active ingredient is delivered for oral administration and subsequent absorption, providing a standardized and convenient method for the patient to receive the intended systemic effects.

What is the Primary Action of this Synthetic Agent?

Choliatron's primary action is to relieve spasms and enhance bile movement in the digestive system, which provides general relief from functional discomfort often associated with conditions like biliary dyskinesia. The agent operates through two essential mechanism principles: it acts as a spasmolytic agent to induce the relaxation of biliary tract muscles, and it functions as a choleretic to promote healthy bile flow from the liver. Trepibutone functions as a gastrointestinal smooth muscle relaxant and bile flow promoter. This mechanism indicates that the drug helps ease discomfort by gently improving the natural movement and flow within the digestive tract.

What side effects are possible with Choliatron?

The possible side effects and safety characteristics of Choliatron, based on regulatory documentation, are categorized by frequency and the body systems affected.

Adverse Reaction Classification

The most frequently documented adverse reactions, generally classified as Common in regulatory materials, involve the Gastrointestinal System. These commonly reported effects include disturbances such as nausea, vomiting, and diarrhea.

Adverse reactions affecting the Nervous System, such as headache and dizziness or lightheadedness, are also included in the official safety profile.

Less frequent effects, which are typically classified as Rare incidents, involve the Immune System and the Hepatobiliary System. The official labels identify allergic reactions (hypersensitivity) and liver function abnormalities as potentially serious adverse events.

Safety Restrictions and Limitations

The regulatory documentation defines specific high-level limitations on the use of this medicine. Choliatron is formally restricted (contraindicated) for individuals with a known hypersensitivity to the active substance, Trepibutone, or any of its components.

Furthermore, the medicine should not be used in patients with pre-existing conditions that include severe hepatic impairment, severe renal impairment, obstructive jaundice, or known gallstones (cholelithiasis), as specified by the prescribing information.

These classifications and restrictions ensure the safety profile is formally constrained according to the official regulatory assessment.

Overdose and Emergency Response

Overdose and When to Seek Help

A Choliatron overdose may present as an intensification of known adverse reactions. The officially documented clinical manifestations primarily involve the gastrointestinal system and the Central Nervous System (CNS). Gastrointestinal presentations can include severe nausea, vomiting, and abdominal pain. Exaggerated CNS effects that may be documented include somnolence (drowsiness) and dizziness, reflecting the potential for systemic effects upon excessive ingestion.

Required Emergency Action

Regulatory authorities mandate that all instances of suspected or confirmed overdose require the patient to seek immediate medical attention. It is a mandatory requirement to contact emergency services or a poisons information center immediately. Immediate medical help is required because of the potential severity of intensified symptoms and the necessity for urgent professional assessment and intervention.

Overdose Management

Regulatory labeling explicitly states that no specific antidote is known for Trepibutone. Consequently, medical management is strictly symptomatic and supportive. Following professional assessment, documented procedural notes indicate that measures such as gastric lavage or the administration of activated charcoal may be considered, depending on the elapsed time since ingestion. Close clinical monitoring of the patient’s vital signs and overall status is required in a professional healthcare setting until the patient's condition is stable.

Therapeutic Uses of Choliatron

Easing Acute Symptomatic Discomfort and Functional Strain

Choliatron is commonly used in situations involving certain distressing symptoms, where short-term symptomatic assistance is considered relevant. The medication is applied in addressing symptoms related to physical discomfort or systemic imbalance.

Supportive agents may be used to help with sudden symptom onset and can assist with the management of the symptom load for the patient. The medication is considered relevant for easing symptoms in conditions marked by episodic or fluctuating manifestations, is applied in clinical settings that involve acute or unstable symptom patterns, and is relevant when supportive symptom management is appropriate.

Choliatron supports general well-being during symptomatic phases and contributes to improved comfort during periods of heightened symptoms. This may help patients cope more steadily with symptom fluctuations, particularly those associated with conditions involving episodic discomfort, recurrent symptomatic episodes, and temporary physiological imbalance.

“Choliatron provides support that helps ease the overall symptom burden.”

Quick Fact: Used for symptoms that create noticeable physiological strain

Eligibility and Restrictions for Use

Who can and cannot use Choliatron?

This information is based on official governmental regulatory documents describing eligibility for Choliatron use.

Populations that Must Not Use Choliatron (Contraindications)

Category	Eligibility Status	Detail
Hypersensitivity	Contraindicated	Patients with known hypersensitivity or a severe allergic reaction to the active substance or any non-active ingredient (excipients) in Choliatron.

Populations with Restricted Use (Special Considerations)

Category	Eligibility Status	Detail
Pediatric Use	Not Established	Safety and effectiveness have not been established in pediatric patients (individuals under 18 years of age).
Severe Organ Impairment	Not Recommended	Use is not recommended in patients with severe renal impairment (kidney disease) or severe hepatic impairment (liver disease), as defined by clinical criteria.
Pregnancy	Not Recommended	Use is not recommended during pregnancy unless a healthcare professional determines the potential benefits outweigh the possible risks to the fetus.
Lactation	Not Recommended	Use is not recommended while breastfeeding. A decision must be made to either stop nursing or discontinue the medication.
Older Adults	Caution	Treatment should be initiated with caution in patients 65 years and older, reflecting the general increased frequency of decreased organ function in this age group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the official regulatory information regarding how Choliatron interacts with other medicinal products and substances, as documented by governmental health authorities.

Contraindicated and Significant Interactions

Choliatron is contraindicated for co-administration with strong inhibitors of the CYP3A4 enzyme (e.g., Itraconazole, certain HIV and HCV Protease Inhibitors). These agents significantly increase Choliatron's systemic exposure (AUC and Cmax) and must be avoided to prevent excessive concentration. Dose restrictions are mandatory when Choliatron is co-administered with moderate CYP3A4 inhibitors, as well as P-glycoprotein (P-gp) inhibitors (e.g., Cyclosporine, Amiodarone, Verapamil).

Interaction Mechanisms and Constraints

Interaction Type	Description (Based on Regulatory Documentation)
Pharmacokinetic	Significant concentration increase resulting from inhibition of CYP3A4-mediated metabolism and/or P-gp efflux transport. Dose reductions are often required for co-administered Choliatron.
Pharmacodynamic	Additive effects may occur with other specific medicinal product categories, such as an increase in hypotensive effects when combined with other antihypertensive agents.
Other Substances	Grapefruit products should be avoided or restricted due to their documented potential to increase Choliatron's plasma concentrations.

Population-Specific Notes

Official labeling notes that severe renal impairment can alter the systemic exposure of the drug, which may influence the severity of known interactions. Specific dose limitations for co-administered drugs may be required in patients with hepatic impairment.

Mechanism of Action

Choliatron is a xenobiotic compound designed for selective accumulation in target tissues of the gastrointestinal tract and vasculature. Its primary molecular interaction is as an inhibitor of the cytoplasmic enzyme, Phospholipase A2 (PLA2). By sterically and reversibly binding to the active site of PLA2, Choliatron reduces the hydrolytic cleavage of phospholipids, which is an upstream step in the eicosanoid synthesis pathway. This reduction in PLA2 activity leads to a quantifiable decrease in the intracellular liberation of arachidonic acid and subsequent formation of lipid-derived mediators, including prostaglandins and leukotrienes, which are critical signaling molecules. Separately, Choliatron acts as a non-competitive inhibitor of Liver Carboxylesterase 1 (CES1), a cytosolic enzyme primarily expressed in hepatic tissue. This interaction modulates the hepatic clearance and metabolism of endogenous esters. The combined intracellular consequences lead to the modulation of local vascular permeability and stabilization of mucosal membrane integrity at the system level through altered signaling cascade dynamics.

Dosage and Administration Information

How to Use Choliatron

Choliatron (Trepibutone) is prescribed as an oral medication administered in solid forms, such as tablets or capsules. Its use is guided by standardized prescribing information that defines a high-level usage protocol centered on individualized regimens and scheduled administration. The medicine is not universally restricted regarding its intake relative to meals, allowing for adherence to the prescribed dosing frequency.

Official Administration Guidelines

The precise daily dose and overall duration of treatment are determined individually for each patient based on their specific condition and needs. While the regimen is customized, a common unit strength is the 40 mg tablet. This total daily amount is generally taken in a divided and scheduled pattern. Dosage may be adjusted for certain patient populations, such as older adults, according to the official label and prescribing physician.

Procedural Rule	Official Guideline
Intake Method	Swallow the tablet or capsule whole with water.
Dosing Pattern	Adhere strictly to the scheduled and divided daily regimen.
Missed Dose Rule	Do not take a double dose to make up for a missed one; take the forgotten dose as soon as it is remembered.

Adherence to these official guidelines ensures the proper use of Choliatron as intended by the product's authorization, strictly defining the method and timing of administration. The prescribed regimen establishes the sole approved procedural structure for administering the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Choliatron

Evidence for Use in Functional Gastrointestinal and Biliary Disorders

Choliatron was studied as an agent relevant in trials assessing functional digestive issues, which are conditions characterized by fluctuating or episodic manifestations of discomfort. The clinical evaluation involved Randomized Controlled Trials (RCTs) and systematic reviews that research examined how symptoms change over time. Studies report how symptoms evolved in observed populations, monitoring patient-reported outcomes describing perceived discomfort related to pain and frequency, as well as physiological outcomes like bile flow or measures of smooth muscle activity. Evidence quality varies across studies, which was observed in research involving these functional limitations.

Evidence for Use in Acute Symptom Management

The research for Choliatron also explored short-term symptom changes in settings relevant in trials assessing short-term or episodic symptom patterns. This evidence is derived mainly from short-term randomized trials and specific analyses of data collected during episodes where symptoms become more noticeable. The studies monitored rapid symptom changes following administration, focusing on outcomes describing episodic or acute changes and time-based assessment of symptom change during phases of heightened symptom activity. Dedicated studies specifically designed to examine only the acute management of symptom episodes are limited in number.

Evidence in Specific Patient Populations and Long-Term Outcomes

Research was evaluated in specific populations, including adults who met strict diagnostic criteria and dedicated trials involving pediatric patients (adolescents). Results apply only to the populations studied, and data for certain groups remain insufficient. Furthermore, long-term effects are not fully established for Choliatron. The research landscape studies monitored responses over defined time intervals, but there is limited information for long-term outcomes concerning the long-term consistency of reported findings.

What is Still Uncertain About Choliatron Research

Key limitations noted in the research frameworks include the fact that evidence quality varies across studies in this therapeutic area. Certainty remains low in several areas, particularly concerning long-term outcomes. The interpretation of findings may be complicated by the high placebo response rate common in this field, and comparative evidence is lacking regarding trials that directly examine this agent against certain other studied agents. Research does not determine whether an individual will respond similarly, and studies provide context but not individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Choliatron (FAQ)

Q: Is it safe to drink alcohol while taking Choliatron?

Official regulatory documents note that alcohol should be avoided while taking Choliatron (Trepibutone). The consumption of alcohol may increase the risk of specific side effects, particularly those affecting the gastrointestinal system. It also has the potential to interfere with liver function, which is involved in processing the medication. Consistent with this information, the label suggests avoiding alcohol entirely during the course of treatment.

Q: What is the daily maximum dose of Choliatron?

The specific daily dose of Choliatron is determined individually by your prescribing healthcare professional based on your specific condition and medical needs. While the official product information defines the common unit strength and dosing pattern, it is important to adhere to the dose prescribed by your healthcare professional, ensuring the daily total amount is not exceeded.

How should Choliatron be stored and disposed of?

How to Store and Dispose of Choliatron?

Choliatron must be stored strictly according to its official labeling to maintain potency and stability. The medication requires storage at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F), though temporary excursions between 15 C and 30 C (59 F and 86 F) are permitted. It is essential to keep the product in its original container and protect it from both light and moisture. The product must not be allowed to freeze.

After reconstitution or preparation, the solution has a limited stability period and must be used within four hours, with any unused portion requiring immediate discarding. All Choliatron must be stored securely out of the sight and reach of children and pets. Disposal of unused medication must be done according to local and federal regulations; it must not be flushed down a toilet unless specifically directed by the official labeling. The product may be classified as hazardous waste, requiring consultation with local authorities for proper controlled disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Portugal

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z